加科思-B午后涨超6% JAB-23E73全球开发进程加速 戈来雷塞有望快速放量

Group 1 - The stock of JACOS-B (01167) rose over 6%, currently at 6.06 HKD with a trading volume of 14.5881 million HKD [1] - In December last year, JACOS announced a collaboration agreement with AstraZeneca for its self-developed Pan-KRAS inhibitor JAB-23E73 [1] - The company’s core pipeline, JAB-23E73, is expected to achieve a peak sales revenue of 1.2 billion RMB in the domestic market, and 1.9 billion USD in overseas markets, adjusted for risk [1] Group 2 - The KRAS G12C inhibitor, Goleirese, is set to be included in the national medical insurance catalog in January 2026, which is anticipated to drive rapid sales growth under the commercialization efforts of Elys [1]